Antiretroviral resistance in HIV: Difference between revisions
From IDWiki
Content deleted Content added
Created page with "* Genotyping sequences reverse transcriptase, integrase, and protease * Resistance point mutations names as wild-type amino acid, position, and mutant amino acid (e.g. K '''10..." |
mNo edit summary |
||
| Line 35: | Line 35: | ||
| Q '''151''' '''M''' |
| Q '''151''' '''M''' |
||
|- |
|- |
||
| rowspan=6 | Thymidine analogue-associated mutations ( |
| rowspan=6 | Thymidine analogue-associated mutations (TAMs) multi-NRTI resistance |
||
| M '''41''' '''L''' |
| M '''41''' '''L''' |
||
|- |
|- |
||
Revision as of 20:06, 5 July 2020
- Genotyping sequences reverse transcriptase, integrase, and protease
- Resistance point mutations names as wild-type amino acid, position, and mutant amino acid (e.g. K 103 N)
- Bulk sequencing can only detect mutations that represent >20% of HIV
| Drug | Mutation |
|---|---|
| NRTIs | |
| 69 insertion complex multi-NRTI resistance | M 41 L |
| A 62 V | |
| * 69 insert | |
| K 70 R | |
| L 210 W | |
| T 215 Y F | |
| K 219 Q E | |
| 151 complex multi-NRTI resistance | A 62 V |
| V 75 I | |
| F 77 L | |
| F 116 Y | |
| Q 151 M | |
| Thymidine analogue-associated mutations (TAMs) multi-NRTI resistance | M 41 L |
| D 67 N | |
| K 70 R | |
| L 210 W | |
| T 215 Y F | |
| K 219 Q W | |
| Abacavir | K 65 R E N |
| L 74 V | |
| Y 115 F | |
| M 184 V | |
| Emtricitabine | K 65 R E N |
| M 184 V I | |
| Lamivudine | K 65 R E N |
| M 184 V I | |
| Tenofovir | K 65 R E N |
| K 70 E | |
| Zidovudine | M 41 L |
| D 67 N | |
| K 70 R | |
| L 210 W | |
| T 215 Y F | |
| K 219 Q E | |
| NNRTIs | |
| Doravirine | V 106 A I M T |
| Y 188 C L H | |
| G 190 E | |
| P 225 H | |
| F 227 C L R | |
| M 230 L | |
| L 234 I | |
| Efavirenz | L 100 I |
| K 101 P | |
| K 103 N S | |
| V 106 M | |
| V 108 I | |
| Y 181 C I | |
| Y 188 L | |
| G 190 S A | |
| P 225 H | |
| M 230 L | |
| Nevirapine | L 100 I |
| K 101 P | |
| K 103 N S | |
| V 106 A M | |
| V 108 I | |
| Y 181 C I | |
| Y 188 C L H | |
| G 190 A | |
| M 230 L | |
| Rilpivirine | L 100 I |
| K 101 E P | |
| E 138 A G K Q R | |
| V 179 L | |
| Y 181 C I V | |
| Y 188 L | |
| H 221 Y | |
| F 227 C | |
| M 230 I L | |
| Protease inhibitors | |
| Atazanavir | L 10 I F V C |
| G 16 E | |
| K 20 R M I T V | |
| L 24 I | |
| V 32 I | |
| L 33 I F V | |
| E 34 Q | |
| M 36 I L V | |
| M 46 I L | |
| G 48 V | |
| I 50 L | |
| F 53 L Y | |
| I 54 L V M T A | |
| D 60 E | |
| I 62 V | |
| I 64 L M V | |
| A 71 V I T L | |
| G 73 C S T A | |
| V 82 A T F I | |
| I 84 V | |
| I 85 V | |
| N 88 S | |
| L 90 M | |
| I 93 L M | |
| Darunavir | V 11 I |
| V 32 I | |
| L 33 F | |
| I 47 V | |
| I 50 V | |
| I 54 M L | |
| T 74 P | |
| L 76 V | |
| I 84 V | |
| L 89 V | |
| I N S T Is | |
| Bictegravir | G 118 R |
| E 138 K | |
| G 140 S | |
| Q 148 H | |
| R 263 K | |
| Cabotegravir | T 66 K |
| G 118 R | |
| E 138 A K T | |
| G 140 A C R S | |
| Q 148 H K R | |
| S 153 F Y | |
| N 155 H | |
| R 263 K | |
| Dolutegravir | G 118 R |
| F 121 Y | |
| E 138 A K T | |
| G 140 A S | |
| Q 148 H K R | |
| N 155 H | |
| R 263 K | |
| Elvitegravir | T 66 I A K |
| E 92 Q G | |
| T 97 A | |
| F 121 Y | |
| S 147 G | |
| Q 148 H K R | |
| N 155 H | |
| R 263 K | |
| Raltegravir | L 74 M |
| E 92 Q | |
| T 97 A | |
| F 121 Y | |
| E 138 A K | |
| G 140 A S | |
| Y 143 R H C | |
| Q 148 H K R | |
| N 155 H | |
| R 263 K | |